Adipotide FTPP (10mg)

Adipotide FTPP is a synthetic peptide, synthesized and lyophilized in the USA. Each batch is HPLC-MS verified above 99% purity and tested by an independent laboratory.

Researchers using Adipotide FTPP (10mg) often combine dose-response assays with stability testing to establish reproducible experimental baselines.

Interest in Adipotide FTPP (10mg) has grown alongside comparative work on incretin-related pathways and substrate utilization in cultured systems.

Adipotide FTPP (10mg) serves as a research tool for examining the interplay between peptide signaling and metabolic endpoints in experimental designs.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Adipotide FTPP (10mg). Summaries are provided for orientation only and reflect the cited sources.

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys^[1] — This study evaluated a peptidomimetic designed to target the vasculature of white adipose tissue in obese monkeys. Treatment led to weight loss and improved insulin resistance in the animals. The findings indicate that selectively ablating white-fat blood vessels can produce metabolic benefits, supporting the proapoptotic approach embodied by compounds such as adipotide. (Science translational medicine 2011)

Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium^[2] — This study examined a peptide engineered to elicit apoptosis in adipose tissue endothelium and its effects on glucose metabolism. The authors reported rapid improvements in glucose tolerance that occurred independently of weight loss. The results suggest that targeting the adipose vasculature can improve metabolic control through mechanisms distinct from body-weight reduction. (Diabetes 2012)

Vascular-targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery^[3] — This study explored vascular-targeted nanotherapy for obesity, describing an unexpected passive targeting mechanism to obese fat that enhances active drug delivery. The authors used prohibitin-homing nanoparticles carrying a proapoptotic peptide payload. The findings illustrate delivery strategies relevant to adipotide-like agents that act on the white-fat vasculature. (Journal of controlled release : official journal of the Controlled Release Society 2012)

Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis^[4] — This study investigated whether ablating stromal cells with a targeted proapoptotic peptide could suppress cancer chemotherapy resistance and metastasis. The authors reported that such ablation reduced resistance and metastatic spread in their experimental models. The findings extend the proapoptotic homing-peptide concept from adipose tissue to the tumor microenvironment. (Molecular therapy oncolytics 2020)

References

1. Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R. "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys." Science translational medicine. 2011. pubmed.ncbi.nlm.nih.gov/22072637/
2. Kim DH, Sartor MA, Bain JR, Sandoval D, Stevens RD, Medvedovic M, Newgard CB, Woods SC, Seeley RJ. "Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium." Diabetes. 2012. pubmed.ncbi.nlm.nih.gov/22733798/
3. Hossen MN, Kajimoto K, Akita H, Hyodo M, Harashima H. "Vascular-targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery." Journal of controlled release : official journal of the Controlled Release Society. 2012. pubmed.ncbi.nlm.nih.gov/22982237/
4. Su F, Wang X, Pearson T, Lee J, Krishnamurthy S, Ueno NT, Kolonin MG. "Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis." Molecular therapy oncolytics. 2020. pubmed.ncbi.nlm.nih.gov/32995482/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.